Difference between revisions of "Team:SYSU-MEDICINE"

Line 19: Line 19:
 
         @font-face{font-family:"HelveticaNeueW02-45Ligh";src:url(https://www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix);src:url(https://www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix) format("eot"),url(https://www.eyeem.com/css/fonts/9a2e4855-380f-477f-950e-d98e8db54eac.woff) format("woff"),url(https://www.eyeem.com/css/fonts/fa82d0ee-4fbd-4cc9-bf9f-226ad1fcbae2.ttf) format("truetype"),url(https://www.eyeem.com/css/fonts/48d599a6-92b5-4d43-a4ac-8959f6971853.svg#48d599a6-92b5-4d43-a4ac-8959f6971853) format("svg")}
 
         @font-face{font-family:"HelveticaNeueW02-45Ligh";src:url(https://www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix);src:url(https://www.eyeem.com/css/fonts/88fcd49a-13c7-4d0c-86b1-ad1e258bd75d.eot?#iefix) format("eot"),url(https://www.eyeem.com/css/fonts/9a2e4855-380f-477f-950e-d98e8db54eac.woff) format("woff"),url(https://www.eyeem.com/css/fonts/fa82d0ee-4fbd-4cc9-bf9f-226ad1fcbae2.ttf) format("truetype"),url(https://www.eyeem.com/css/fonts/48d599a6-92b5-4d43-a4ac-8959f6971853.svg#48d599a6-92b5-4d43-a4ac-8959f6971853) format("svg")}
 
         *{
 
         *{
−
             font-family:"HelveticaNeueW02-45Ligh","Arial",sans-serif;
+
             font-family:"Arial",sans-serif;
 
             letter-spacing: 0.4px;
 
             letter-spacing: 0.4px;
 
             line-height: 1.5em;
 
             line-height: 1.5em;
 
         }
 
         }
 
         #HQ_page h1,#HQ_page h2,#HQ_page h3,#HQ_page h4,#HQ_page h5,#HQ_page p{
 
         #HQ_page h1,#HQ_page h2,#HQ_page h3,#HQ_page h4,#HQ_page h5,#HQ_page p{
−
             font-family:"HelveticaNeueW02-45Ligh","Arial",sans-serif;
+
             font-family:"Arial",sans-serif;
 
         }
 
         }
 
         #HQ_page p{
 
         #HQ_page p{

Revision as of 04:22, 13 October 2016

MSCavalry

-----MSCs of
next generation

Inflammatory diseases are an increasing cause of disability and even fatality. Currently, apart from common treatments, MSCs therapy is a promising candidate for curing inflammatory diseases. However, intravascular injected MSCs are criticized for its low homing efficiency and ambiguous distribution in human body.

This year, MSCavalry: MSCs of next generation is coming. SYSU-MEDICINE decide to engineer a set of MSCs (homo sapiens) with higher accuracy and we hope that our project can pave the way for future MSCs clinical application.